ALTSTATION.IO

ResMed Inc. (RMD) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$269.58

Change

+0.95%

Market Cap

$39.35B

Avg Volume

1.0M

Company Overview

ResMed Inc. specializes in creating medical devices and cloud-based software aimed at diagnosing and managing respiratory disorders, particularly sleep apnea. Their product lineup includes diagnostic tools like ApneaLink Air and NightOwl, as well as cloud platforms such as AirView for remote patient monitoring. Their primary customers include hospitals, sleep clinics, and home care providers, making their products essential for both clinical and at-home settings.

ResMed is a market leader in the respiratory health space, primarily due to its advanced technology and comprehensive product offerings. Competitors like Philips and Fisher & Paykel Healthcare challenge ResMed, but the company differentiates itself with its robust cloud-based solutions and user-friendly applications. However, the growing market for telehealth poses a threat, as alternative solutions emerge that offer similar services without the need for physical devices.

Currently, ResMed is in a growth phase, driven by increasing demand for sleep apnea solutions and rising healthcare awareness. They are strategically expanding their software capabilities, which has been a focus in recent quarters. Recently, ResMed announced the acquisition of a key software solution provider, Brightree, enhancing its market presence in the home medical equipment segment. This move reflects a pivot towards integrated healthcare solutions, positioning ResMed well for future expansion.

Key Financials

Market Cap

$39.35B

Revenue

$5.40B

EBITDA

$2.02B

Gross Margin

61.5%

Profit Margin

27.5%

Revenue Growth

11.0%

Total Cash

$1.42B

Total Debt

$847.72M

Free Cash Flow

$1.42B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

26.64

Forward P/E

22.13

Beta

0.88

52-Week High

$293.81

52-Week Low

$199.92

EPS

$10.12

50-Day Avg

$251.84

200-Day Avg

$258.87

Price/Book

6.21

Technical Analysis

The overall trend for ResMed Inc. (RMD) over the past 52 weeks has been upward, with a solid increase of approximately 14.9%. The stock started the year around $240 and has reached a current price of $269.58, demonstrating consistent gains despite minor pullbacks. Key support is identified around $240, while resistance seems to be at approximately $271.63, as evidenced by the price action in recent months. Notable price formations include a series of higher lows and higher highs, suggesting a bullish trajectory. Recently, the momentum has picked up, especially evident in the movement towards the current price, where it sits near the upper end of the 52-week range of $200 to $271.63. Being at $269.58 indicates that the stock is leveraging strong bullish sentiment as it approaches its historical resistance level, implying potential for breakout or consolidation in the near term.

Recent News and Developments

Here’s a summary of the latest news and developments for ResMed Inc

(RMD) stock in the past week:

1. ResMed Exceeds Q2 FY26 Earnings and Revenue Expectations, Boosts Dividend

ResMed Inc. reported strong financial results for its second quarter of fiscal year 2026, with adjusted earnings per share (EPS) reaching $2.81, a 15.6% increase year-over-year and beating the Zacks Consensus Estimate by 4.59%. Revenue for the quarter rose 11% to $1.4 billion (9% in constant currency), driven by robust demand for its sleep and respiratory care devices, particularly masks and accessories. The company also declared a quarterly cash dividend of $0.60 per share, payable on March 19, 2026. Gross margin expanded by 320 basis points to 61.8% (62.3% non-GAAP), attributed to manufacturing and logistics efficiencies and component cost improvements.

2. Analysts Raise Price Targets Following Strong Earnings Report

Following ResMed’s impressive Q2 FY26 earnings, several analysts updated their ratings and price targets for RMD stock. RBC Capital, for instance, raised its price target for ResMed to $314, citing double-digit revenue and earnings growth that surpassed both their own and consensus estimates. KeyBanc Capital Markets also adjusted its price target upward to $302, describing the financial results as largely positive and supportive of its investment thesis. Overall, ResMed maintains a “Buy” consensus rating from analysts, with a median price target of $300.00, implying a potential 16.1% upside from its recent trading price of $258.31.

Market Sentiment and Analyst Recommendations

Bull Case

ResMed is firing on all cylinders right now. Q2 earnings crushed expectations with 15.6% EPS growth and 11% revenue growth, while gross margins expanded 320 basis points to 61.8% — that’s real operational leverage, not accounting tricks. The company is sitting on $1.42B in net cash (after subtracting $847.72M debt) with a fortress balance sheet, and they’re returning capital through dividend hikes. The AI-enabled Smart Comfort device and F30i mask launch are legitimate product innovations that address patient adherence, which is the actual problem in sleep apnea therapy. At a 26.64 P/E with 15 analysts recommending buy and median price target of $300, the stock still has 11% upside to consensus, and that’s before factoring in potential margin expansion or market share gains in the $5.40B revenue base. The stock’s 14.9% gain over 52 weeks reflects justified momentum, not hype.

Bear Case

The valuation is stretched for a medical device company with single-digit organic growth. A 26.64 P/E multiple on 11% revenue growth leaves little room for disappointment, and the stock is already sitting near $270 with resistance evident at $271.63. The broader medtech space faces persistent pricing pressure and reimbursement headwinds that ResMed can’t escape — masks and accessories are commoditizing, which is why the company needs AI gimmicks like Smart Comfort to justify premium pricing. Executive insiders are selling stock (CFO sold 1,000 shares at $257, general counsel sold shares at $260), which is a subtle red flag on conviction. If margin expansion stalls or growth deceleration hits in the next quarter, the stock has limited downside cushion. The analyst target range is wide ($230-$345), suggesting genuine disagreement on fair value.

What to Watch

Monitor Q3 FY26 earnings for margin sustainability — can ResMed hold that 62% non-GAAP gross margin or does it compress? Watch adoption metrics on the Smart Comfort device and F30i masks in the earnings call; if these innovations don’t drive material revenue acceleration beyond 11%, the valuation story breaks. Track the stock’s behavior at the $271.63 resistance level; a clean breakout signals institutional confidence, but failure to break through suggests consolidation or pullback toward $240 support. Keep tabs on reimbursement policy changes and any pricing pressure in the mask category, which is their highest-margin business. Monitor debt reduction progress — they have $1.42B in cash, so accelerated deleveraging would unlock capital for M&A or buybacks. Finally, watch insider buying patterns; if executives start accumulating shares again instead of selling, that’s a real vote of confidence after the recent stock run.

Analyst Consensus

BUY

Based on 15 analyst opinions

Low Target

$230.00

Mean Target

$297.47

High Target

$345.00

Earnings and Financial Data

Sector

Healthcare

Industry

Medical Instruments & Supplies

Employees

N/A

Earnings & Dividends

Next Earnings

Jan 29, 2026

EPS (Trailing)

$10.12

Dividend Yield

90.0%

Payout Ratio

22.4%

Frequently Asked Questions

Is RMD a good stock to buy?

Yes, RMD is currently rated as a “BUY” by analysts, with a target price of $297.47. Given its solid P/E ratio of 26.64 and growth potential, it presents an attractive investment opportunity.

What is RMD’s price target?

Analysts have set a price target of $297.47 for ResMed Inc. This represents a potential upside of about 10.3% from its current price of $269.58.

Does RMD pay a dividend?

Yes, ResMed Inc. offers a dividend yield of 90.0%. This makes it a compelling choice for income-focused investors.

What is RMD’s 52-week price range?

RMD’s stock has traded between $199.92 and $293.81 over the past year. This range indicates a healthy level of volatility and trading activity.

How does RMD’s market cap compare to its industry?

With a market cap of $39.35 billion, RMD is a sizable player in the healthcare sector, specifically in medical instruments and supplies. Its strong financial position allows it to leverage growth opportunities effectively.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.